OIA
SRPT icon

Optimum Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Optimum Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-150
Closed -$24K – 1029
2018
Q3 		$24K Hold
150
– – 0.01% 691
2018
Q2 		$20K Buy
+150
New +$14.1K 0.01% 737

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Optimum Investment Advisors's SRPT Position: Q4 2018 in Review

Optimum Investment Advisors sold out of Sarepta Therapeutics (SRPT) in Q4 2018, closing a stake of 150 shares — an estimated $24K sold.

Optimum Investment Advisors first reported a position in SRPT in Q2 2018 and held it in 2 quarters. The position peaked at $24K in Q3 2018. 336 funds tracked by Wall St. Rank hold SRPT as of Q4 2018.

  • Optimum Investment Advisors reported no remaining Sarepta Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Optimum Investment Advisors sold 150 Sarepta Therapeutics shares in Q4 2018, an estimated $24K.
  • Optimum Investment Advisors first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 2 quarters.
  • Optimum Investment Advisors's Sarepta Therapeutics position peaked at $24K in Q3 2018.
  • 336 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2018.

Based on Optimum Investment Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.